Interleukin-3 is a predictive marker for severity and outcome during SARS-CoV-2 infections

  1. Alan Bénard
  2. Anne Jacobsen
  3. Maximilian Brunner
  4. Christian Krautz
  5. Bettina Klösch
  6. Izabela Swierzy
  7. Elisabeth Naschberger
  8. Torsten Birkholz
  9. Ixchel Castellanos
  10. Denis Trufa
  11. Horia Sirbu
  12. Marcel Vetter
  13. Andreas E. Kremer
  14. Kai Hildner
  15. Andreas Hecker
  16. Fabian Edinger
  17. Matthias Tenbusch
  18. Enrico Richter
  19. Hendrik Streeck
  20. Marc M. Berger
  21. Thorsten Brenner
  22. Markus A. Weigand
  23. Filip K. Swirski
  24. Georg Schett
  25. Robert Grützmann
  26. Georg F. Weber
1 evaluations Published on
Read the full article Related papers
This article on Sciety

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a worldwide health threat. Here, we report that low plasma interleukin-3 (IL-3) levels were associated with increased severity and mortality during SARS-CoV-2 infections. IL-3 promoted the recruitment of antiviral circulating plasmacytoid dendritic cells (pDCs) into the airways by stimulating CXCL12 secretion from pulmonary CD123+epithelial cells. This study identifies IL-3 as a predictive disease marker and potential therapeutic target for SARS-CoV-2 infections.

Related articles

Related articles are currently not available for this article.